Danison Emmerson: A New Chapter in Stroke Prevention for Dialysis Patients
Danison Emmerson, Vascular neurologist, UMass Memorial Medical Center, shared a post on LinkedIn:
“A New Chapter in Stroke Prevention for Dialysis Patients: Closing the Gap, Literally
A recent JAMA Network Open study by Dhar et al. (2025) offers encouraging data on left atrial appendage closure (LAAC) in patients with atrial fibrillation on dialysis — a group notoriously difficult to manage for stroke prevention.
Read the study
As a Vascular neurologist, I find this especially relevant. In dialysis patients, effective anticoagulation is often more aspirational than achievable — complicated by uremic platelet dysfunction, shifting pharmacokinetics, and procedural interruptions. Even with close monitoring, we rarely know if patients are truly protected or just trading one risk for another.
That’s why I view LAAC as a favorable alternative to lifelong oral anticoagulation in this population. The study found:
- Lower bleeding risk compared with oral anticoagulants
- Reduced all-cause mortality
- No significant increase in stroke events
This mechanical solution may offer the most stable path to stroke prevention in patients for whom consistent anticoagulation is clinically elusive. From a systems perspective, it also aligns with precision medicine — tailoring prevention to physiology, not protocol.
Randomized data (such as the upcoming LAA-KIDNEY trial) will be critical, but this represents a meaningful step toward rethinking how we protect some of our most complex patients from devastating cerebrovascular events.
“In dialysis-associated atrial fibrillation, achieving therapeutic anticoagulation isn’t just challenging — it’s uncertain. LAAC may finally close that gap.”
References:
Dhar R, Sandhu GS, et al. JAMA Netw Open. 2025;8(10):e2838656
Genovesi S, Camm AJ. JAMA Netw Open. 2025;8(10):e2838656
Siontis KC et al. Circulation. 2018;138:1519–1529
Holmes DR Jr et al. JACC. 2019;74:287–297″
Stay updated with Hemostasis Today.
-
Oct 10, 2025, 16:15Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
-
Oct 10, 2025, 12:21Chris Barber Echoes PPTA’s Call to Recognize the Lifesaving Work of Plasma Collection Teams Worldwide
-
Oct 10, 2025, 12:14William Aird: Thalassemia Trait is a Quiet Experiment of Nature
-
Oct 9, 2025, 19:53Wilfried Dinh: Top 10 Thrombosis And Antithrombotic Therapy Papers Of 2024
-
Oct 9, 2025, 13:12Abdul Mannan - Ferritin After IV Iron: Timing Matters
-
Oct 10, 2025, 12:23Bhavya Venkatesh: Talin Autoinhibition Is Required For Normal Hemostasis
-
Oct 10, 2025, 12:19Divyaswathi Citla Sridhar: Excited to Share Our Multicenter Study on Platelet Function Disorders, Now Published
-
Oct 10, 2025, 12:18Roberta Gualtierotti: We Evaluated Different Variables of the Cleaved HK Method in C1-Inhibitor Defects
-
Oct 10, 2025, 12:17Jamie Madrigal And The Team - Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
-
Oct 10, 2025, 03:09Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?
-
Oct 10, 2025, 03:06Anita Brikman: Increasing Awareness of The Ongoing Need for Plasma Donors Is Vital to Ensuring Patient Access and Continuity of Care
-
Oct 10, 2025, 03:04Stephen Cornelissen: A New Plasma Drop Has Been Added to Lifeblood’s Blood Supply Tracker
-
Oct 10, 2025, 02:12Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic